Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OCX
- Price
- 3.16
- Stock movement down
- -0.04 (-1.25%)
- Company name
- OncoCyte Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 53.20M
- Ent value
- 110.34M
- Price/Sales
- 75.03
- Price/Book
- 5.48
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -15.29%
- 1 year return
- 14.49%
- 3 year return
- -47.94%
- 5 year return
- -41.62%
- 10 year return
- -
Last updated: 2025-06-22
DIVIDENDS
OCX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 75.03 |
| Price to Book | 5.48 |
| EV to Sales | 155.63 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 16.84M |
| EPS (TTM) | -3.15 |
| FCF per share (TTM) | -1.50 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 709.00K |
| Gross profit (TTM) | -330.00K |
| Operating income (TTM) | -28.93M |
| Net income (TTM) | -43.14M |
| EPS (TTM) | -3.15 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -46.54% |
| Operating margin (TTM) | -4080.54% |
| Profit margin (TTM) | -6085.19% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.36M |
| Net receivables | 209.00K |
| Total current assets | 4.79M |
| Goodwill | 0.00 |
| Intangible assets | 56.53M |
| Property, plant and equipment | 13.55M |
| Total assets | 70.22M |
| Accounts payable | 872.00K |
| Short/Current long term debt | 3.99M |
| Total current liabilities | 9.09M |
| Total liabilities | 60.51M |
| Shareholder's equity | 9.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -19.92M |
| Capital expenditures (TTM) | 694.00K |
| Free cash flow (TTM) | -20.61M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -444.28% |
| Return on Assets | -61.44% |
| Return on Invested Capital | -392.43% |
| Cash Return on Invested Capital | -187.51% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.04 |
| Daily high | 3.23 |
| Daily low | 2.76 |
| Daily Volume | 1.44M |
| All-time high | 202.20 |
| 1y analyst estimate | 4.13 |
| Beta | 1.00 |
| EPS (TTM) | -3.15 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| OCX | S&P500 | |
| Current price drop from All-time high | -98.44% | -2.53% |
| Highest price drop | -99.03% | -56.47% |
| Date of highest drop | 22 Jan 2025 | 9 Mar 2009 |
| Avg drop from high | -75.50% | -11.04% |
| Avg time to new high | 794 days | 12 days |
| Max time to new high | 2378 days | 1805 days |
COMPANY DETAILS
Marketcap
53.20M
Marketcap category
Small-cap
Description
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Employees
43
Website
Investor relations
-
SEC filings
CEO
Ronald Asbury Andrews
Country
USA
City
Irvine
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner